yahoo_financeOriginal article
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Phase 1PaxalisibPositive
AI Analysis
Summary
Kazia Therapeutics announced that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of Paxalisib for rare seizure disorders.
Clinical Trial Data
Phase
1b/2a
Outcome Details
First patient dosed in Phase 1b/2a trial
Importance:5/10
Sentiment:
0.30
rare_diseaseseizure_disordersphase_1b_2atrial_initiation
Related Companies
Read the original article
Published by yahoo_finance on September 22, 2026 11:30 AM